ClinicalTrials.gg
RecruitingNCT06997588Updated Nov 10, 2026

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

A Phase 2 interventional study of Alpelisib in PIK3CA-related Overgrowth Spectrum (PROS), sponsored by Novartis Pharmaceuticals. Recruiting at 41 sites in 11 countries. Open to participants aged 2 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 10, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
2 Years to 100 Years
Sex
All
01

Study summary

This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spectrum (PROS).

Read the detailed description

The study consists of a core period of 48 weeks and an extension period of up to 2 years to assess the efficacy, safety and pharmacokinetic (PK) of alpelisib in pediatric and adult participants with PROS.

Screening Period: Potential participants will be assessed for eligibility and undergo a whole body MRI scan to evaluate PROS-related lesions. Only those who meet all inclusion criteria will be eligible for randomization.

Core Period: Baseline is defined as the last available evaluation prior to the first dose of study treatment. Participants in Group 1 and Group 2 will be enrolled and treated with alpelisib in an open-label fashion.

  • Group 1 (adults): will start with 250 mg once daily, with no dose escalation allowed.
  • Group 2 (children and adolescents): will start with 50 mg once daily for participants aged 2 to \<6 years, and 125 mg once daily for participants aged 6 to \<18 years.

Extension 1 Period: Participants in both groups will continue their treatment under the same rules as the core period. This period will last until Week 168 following the completion of the core period for each participant. Those who complete this period before the end of the study will transition to the Extension 2 period.

Extension 2 Period: Participants will continue their treatment under the same rules as the core and Extension 1 periods until the last participant completes the Extension 2 period. Participants still deriving clinical benefit from alpelisib at the end of the study may receive post-trial access (PTA) to alpelisib.

02

Conditions studied

  • PIK3CA-related Overgrowth Spectrum (PROS)

Keywords

  • PIK3CA-related overgrowth spectrum (PROS)
  • Alpelisib (BYL719)
  • Phase II
  • Adult
  • Pediatric
  • Adolescent
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
2 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female participants aged ≥2 years at the time of /assent.
  2. Participants with diagnosis of PROS (according to Clinical Diagnostic Criteria for PROS proposed by Keppler Noreuil et al 2014) with symptomatic AND progressive overgrowth, who have syndromic disease or isolated features (with the exception of isolated macrodactyly, macrocephaly or epidermal nevus) at the time of informed consent/assent.
  3. Documented evidence of a somatic mutation(s) in the PIK3CA gene performed in local laboratories using a DNA-based test AND available (if archival tissue sample is not available, a fresh biopsy should be performed, if it is not clinically ) at the time of informed consent/assent.
  4. (in participants >16 years of age at study entry) or Lansky (≤16 years of age at study entry) performance status index ≥50.
  5. PGI-S score of mild, moderate, severe, or very severe at screening.
  6. Adequate bone marrow and organ function.
  7. Presence of at least 1 PROS-related (longest diameter ≥2 cm) confirmed by BIRC assessment and associated with complaints, clinical symptoms or functional limitations affecting the participant's everyday life.

Key Exclusion Criteria:

  1. Participant with only isolated macrodactyly, epidermal nevus/nevi and macroencephaly (the only clinical feature or a combination of any of three of them), in absence of other PROS-related lesions at the time of informed consent/assent.
  2. Previous treatment with alpelisib and/or any other phosphatidylinositol 3-kinase (PI3K) inhibitor(s) (except treatment attempt, defined as the attempt to treat PROS with any of PI3K inhibitors, with treatment duration less than 2 weeks and stopped at least 2 weeks prior to the first dose of study medication with alpelisib).
  3. Debulking or other major surgery performed within 3 months at the time of informed consent/assent.
  4. Radiation exposure for PROS treatment purpose within 12 months prior to informed consent/assent.
  5. PROS-related thrombotic event (Grade 2 and more as per v4.03) within 15 days before study treatment initiation, and/or sclerotherapy/embolization for vascular complications performed within 6 weeks before informed consent/assent.
  6. Clinically meaningful bleeding from PROS-related lesion (Grade 2 and more as per CTCAE v4.03) within 15 days before study treatment initiation.
  7. Participants with clinically significant worsening of PROS-related laboratory abnormalities, physical signs and symptoms (such as, but not limited to increase of D-dimers, worsening of underlying pain, newly occurring swelling or redness) indicating an uncontrolled condition during the screening phase.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Group 1

    Adult participants ≥18 years of age.

    Drug: Alpelisib

  • Experimental
    Group 2

    Children and adolescents 2 to \<18 years of age.

    Drug: Alpelisib

Interventions

  • Oral Film-Coated Tablet (FCT): * Group 1: 250 mg once daily * Group 2, 6 to \<18 years: 125 mg once daily (starting dose) Granules: • Group 2, 2 to \<6 years: 50 mg once daily (starting dose)

    Also known as: BYL719

06

What researchers measure

Primary outcomes

  1. Proportion of participants with a confirmed objective response by BIRC

    Confirmed objective response is defined as achieving radiological response, confirmed by a subsequent assessment performed at least after 4 weeks. The achievement of radiological response requires ≥20% reduction from baseline in the sum of target lesion volumes (1 to 3 target lesions, assessed by Magnetic Resonance Imaging (MRI) by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥20% increase from nadir, and in absence of progression of non-target lesions and without new lesions.

    Time frame: Up to Week 48

Secondary outcomes

  1. Proportion of participants with a confirmed objective response by BIRC in a protocol-defined subset of patients

    Confirmed objective response is defined as achieving radiological response, confirmed by a subsequent assessment performed at least after 4 weeks. The achievement of radiological response requires ≥20% reduction from baseline in the sum of target lesion volumes (1 to 3 target lesions, assessed by Magnetic Resonance Imaging (MRI) by a blinded independent review committee (BIRC)), provided that none of the individual target lesions has ≥20% increase from nadir, and in absence of progression of non-target lesions and without new lesions.

    Time frame: Up to Week 48

  2. Change from baseline (as assessed by BIRC) in target lesion volume

    Change from baseline (as assessed by BIRC) in target lesion volume will be summarized descriptively

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  3. Change from baseline (as assessed by BIRC) in MRI-measurable non-target lesion volume

    Change from baseline (as assessed by BIRC) in MRI-measurable non-target lesion volume will be summarized descriptively

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  4. Change from baseline (as assessed by BIRC) in all MRI-measurable (target and non-target) lesion volume

    Change from baseline (as assessed by BIRC) in all MRI-measurable (target and non-target) lesion volume will be summarized descriptively

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  5. Change from baseline (as assessed by BIRC) in other non-target lesion

    Change from baseline (as assessed by BIRC) in other non-target lesion will be summarized descriptively

    Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  6. Appearance of new lesions (as assessed by BIRC)

    Appearance of new lesions (as assessed by BIRC) will be summarized descriptively

    Time frame: Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  7. Proportion of participants with a radiological response

    Time frame: Week 12, Week 24, Week 48, Week 96, Week 144, Week 168, End of Treatment (last dose +< 14 day - Only for participants discontinuing on or prior to week 168)

  8. Duration of Response (DoR)

    Duration of response (DOR) is defined as the time from the first documented confirmed objective response until progression of any PROS lesion by BIRC or death or rescue surgery for any PROS lesion.

    Time frame: From first documented response until progression of PROS lesions or death, assessed up to approximately 3 years

  9. Alpelisib plasma concentration

    Time frame: Week 1 Day 1 (Post-dose 3 hour), Week 4 Day 1 (Pre-dose and Post-dose 3 hour), Week 12 Day 1 (Pre-dose and Post-dose 3 hour)

  10. Change from Baseline in Brief Pain Inventory (BPI)

    Two items from the Brief Pain Inventory (BPI) will be used for adult and pediatric participants aged 12 years and older. The first item assesses the worst pain intensity in the past 24 hours, with responses on an 11-point scale from 0 (no pain) to 10 (pain as bad as you can imagine). The second item evaluates pain interference with general activity in the past 24 hours, also on an 11-point scale from 0 (does not interfere) to 10 (completely interferes).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, End of Treatment (last dose +< 14 days)

  11. Change from Baseline in Wong-Baker Faces Scale

    For children aged 3-11 years, the Wong-Baker FACES® Pain Rating Scale will be used instead of the BPI worst pain intensity question. This scale features six faces showing increasing levels of pain, each with a numeric rating and a descriptor (from 0 'no hurt' to 10 'hurts worst'). Children will select the face that best represents their pain level. There is no pain intensity scale for children under 3 years.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, End of Treatment (last dose +< 14 days)

  12. Change from Baseline in Patient Global Impression of Symptom Severity (PGI-S)

    A Patient Global Impression of Symptom Severity (PGI-S) item will be used to understand the overall severity of symptoms experienced and clinical meaningfulness of treatment effects experienced during this study. This item includes 5 response options: no symptoms, mild, moderate, severe, and very severe. This scale can be completed by the parent/caregiver for pediatric participants aged \<12 years.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 24, Week 48, Week 72, Week 96, Week 120, Week 144, Week 168, End of Treatment (last dose +< 14 days)

  13. Time to Treatment Failure (TTF)

    Time to Treatment Failure (TTF) is defined as the time from alpelisib treatment start date until disease progression supported by radiological assessment performed by BIRC, death, rescue surgery for any PROS lesion or discontinuation of alpelisib due to any reason other than technical problems or study termination by the sponsor. Participants who complete the study, are ongoing treatment or discontinue alpelisib due to technical problems (e.g. drug supply issues, site prematurely ends study participation) or study termination by the sponsor will be censored at the date of last study treatment received.

    Time frame: From Baseline up to approximately 3 years

  14. Overall Clinical Response

    The proportion of participants with overall clinical response reported as improvement, stable or worsening of clinical condition, as assessed by the Investigator will be summarized descriptively.

    Time frame: From Baseline up to approximately 3 years

  15. Change from Baseline in symptoms and complications/comorbidities associated with PROS

    Changes in symptoms and complications/comorbidities (i.e., walking impairment, cardiac/pulmonary/renal function, pain, Karnofsky/Lansky performance status) will be summarized descriptively. For each complication/comorbidity, only participants who have this reported as being present at baseline will be included in the analysis. When new symptoms/complications/comorbidities appear at any time of study therapy, they will be assessed for clinical significance and reported as adverse events when applicable.

    Time frame: From Baseline up to approximately 3 years

  16. Percentage of participants with healthcare visits/hospitalized due to PROS

    Percentage of participants with healthcare visit/hospitalized due to PROS will be assessed for Group 1 and Group 2.

    Time frame: Up to at least 3 years

  17. Percentage of participants with surgeries required to manage PROS

    Percentage of participants requiring rescue surgery due to PROS will be assessed for Group 1 and Group 2.

    Time frame: Up to at least 3 years

  18. Number of Adverse Events and Serious Adverse Events as assessed by CTCAE criteria

    Treatment emergent Adverse Event (TEAEs) in this study were events that started after the first dose of study treatment and until 30 days after the last dose of study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 30 days after the last study treatment.

    Time frame: Up to at least 3 years

07

Study locations

41 of 41 sites recruiting
  • Univ of California at Sacramento
    Sacramento, California 95817, United States
    Recruiting
  • Childrens National Medical Center
    Washington D.C., District of Columbia 20010-2970, United States
    Recruiting
  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • Cinn Children Hosp Medical Center
    Cincinnati, Ohio 45229-3039, United States
    Recruiting
    • Sarah Price · ContactSarah.Price@cchmc.org · 513-636-7374
    • Adrienne Hammill · Principal investigator
  • Nationwide Children s Hospital
    Columbus, Ohio 43205, United States
    Recruiting
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
    Recruiting
    • Annie Yang · Contactyangann@ohsu.edu · 503-494-5742
    • Melinda Wu · Principal investigator
  • Childrens Hosp Pittsburgh UPMC
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Alex Berkebile · Contactberkebileak@upmc.edu · 412-692-5346
    • Julia Segal · Principal investigator
  • Baylor College Of Medicine
    Houston, Texas 77030, United States
    Recruiting
  • UT Health Science Center
    Houston, Texas 77030, United States
    Recruiting
  • Childrens Hospital and Regional Medical Center
    Seattle, Washington 98105, United States
    Recruiting
  • Novartis Investigative Site
    Sydney, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    Sydney, New South Wales 2031, Australia
    Recruiting
  • Novartis Investigative Site
    North Adelaide, South Australia 5066, Australia
    Recruiting
  • Novartis Investigative Site
    Salzburg, 5020, Austria
    Recruiting
  • Novartis Investigative Site
    Vienna, 1090, Austria
    Recruiting
  • Novartis Investigative Site
    Ghent, 9000, Belgium
    Recruiting
  • Novartis Investigative Site
    Angers, 49933, France
    Recruiting
  • Novartis Investigative Site
    Bron, 69677, France
    Recruiting
  • Novartis Investigative Site
    Dijon, 21000, France
    Recruiting
  • Novartis Investigative Site
    Montpellier, 34295, France
    Recruiting
  • Novartis Investigative Site
    Paris, 75015, France
    Recruiting
  • Novartis Investigative Site
    Toulouse, 31400, France
    Recruiting
  • Novartis Investigative Site
    Tours, 37044, France
    Recruiting
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
    Recruiting
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
    Recruiting
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06120, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 13353, Germany
    Recruiting
  • Novartis Investigative Site
    Stuttgart, 70374, Germany
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00168, Italy
    Recruiting
  • Novartis Investigative Site
    Torino, TO 10126, Italy
    Recruiting
  • Novartis Investigative Site
    Trieste, TS 34137, Italy
    Recruiting
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
    Recruiting
  • Novartis Investigative Site
    Esplugues, Barcelona 08950, Spain
    Recruiting
  • Novartis Investigative Site
    A Coruña, 15006, Spain
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08035, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28046, Spain
    Recruiting
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
    Recruiting
  • Novartis Investigative Site
    Liverpool, L12 2AP, United Kingdom
    Recruiting
  • Novartis Investigative Site
    London, WC1N 3JH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 39 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2028 → Jan 2029 and completion Sep 2030 → Jun 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
May 30, 2025
StartActual
Oct 9, 2025
Primary completionEst.
Jan 29, 2029was Aug 2028
CompletionEst.
Jun 18, 2031was Sep 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Univ of California at Sacramento · Sacramento, United States
  • Childrens National Medical Center · Washington D.C., United States
across 2 updates, Nov 3, 2026 – Nov 10, 2026
Primary completion
Aug 2, 2028→Jan 29, 2029
Oct 5, 2026
Study completion
Sep 30, 2030→Jun 18, 2031
Oct 5, 2026
Enrollment
104→140
Oct 5, 2026
Eligibility
3 criteria edited
What changed in the criteria
  • EditedPrevious treatment with alpelisib and/or any other phosphatidylinositol 3-kinase (PI3K) inhibitor(s) (except treatment attempt, defined as the attempt to treat PROS with any of PI3K inhibitors, with treatment duration less than 2 weeks and stopped at least 42 weeks prior to the first dose of study medication with alpelisib).
  • EditedClinically meaningful PROS-related thrombotic event (Grade 2 and more as per CTCAE v4.03) within 3015 days before informed consent/assentstudy treatment initiation, and/or sclerotherapy/embolization for vascular complications performed within 6 weeks before informed consent/assent.
  • EditedClinically meaningful bleeding from PROS-related lesion (Grade 2 and more as per CTCAE v4.03) within 3015 days before study treatment initiation.
Oct 5, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedProportion of participants with a confirmed objective response by BIRC in a protocol-defined subset of patientsTime frame: Up to Week 48
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Childrens Hospital and Regional Medical Center · Seattle, United StatesContact t•••@seattlechildrens.org · •••2100→s•••@seattlechildrens.org · •••2100
across 3 updates, Oct 5, 2026 – Nov 10, 2026
Show all 4 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • Childrens National Medical Center · Washington D.C., United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Childrens Hospital and Regional Medical Center · Seattle, United StatesContact t•••@seattlechildrens.org · •••2100→s•••@seattlechildrens.org · •••2100
  2. Nov 3, 2026
    1 site added
    Show site
    • Univ of California at Sacramento · Sacramento, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Childrens Hospital and Regional Medical Center · Seattle, United StatesContact s•••@seattlechildrens.org · •••2100→t•••@seattlechildrens.org · •••2100
    + 1 other change: verification date
  3. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date
  4. Oct 5, 2026
    Primary completion Aug 2, 2028→Jan 29, 2029
    Study completion Sep 30, 2030→Jun 18, 2031
    Enrollment 104→140
    Eligibility 3 criteria edited
    What changed in the criteria
    • EditedPrevious treatment with alpelisib and/or any other phosphatidylinositol 3-kinase (PI3K) inhibitor(s) (except treatment attempt, defined as the attempt to treat PROS with any of PI3K inhibitors, with treatment duration less than 2 weeks and stopped at least 42 weeks prior to the first dose of study medication with alpelisib).
    • EditedClinically meaningful PROS-related thrombotic event (Grade 2 and more as per CTCAE v4.03) within 3015 days before informed consent/assentstudy treatment initiation, and/or sclerotherapy/embolization for vascular complications performed within 6 weeks before informed consent/assent.
    • EditedClinically meaningful bleeding from PROS-related lesion (Grade 2 and more as per CTCAE v4.03) within 3015 days before study treatment initiation.
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedProportion of participants with a confirmed objective response by BIRC in a protocol-defined subset of patientsTime frame: Up to Week 48
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Childrens Hospital and Regional Medical Center · Seattle, United StatesContact t•••@seattlechildrens.org · •••2100→s•••@seattlechildrens.org · •••2100
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06997588
Responsible party
Sponsor
First posted
May 30, 2025
Start date
Oct 9, 2025
Primary completion
Jan 29, 2029 (estimated)
Completion
Jun 18, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpelisib

Start the discussion